

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

19-06-2001


GB 000001086

ARTICLE 34

40

Claims

1. A compound for use in medicine with formula (a) or (b):-




wherein:

R₁ and R₂ are, independently, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaromatic or heteroalicyclic,

R₃ and R₄ are hydrogen,

R₅ and R₆ are, independently, hydrogen or a halogen,

and X has the formula:-





19-06-2001

GB 000001086

41

wherein R_7 , R_8 and R_9 are, independently, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted alkoxy, substituted or unsubstituted aminoalkyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaromatic or heteroalicyclic, and a is absent or a linking group, optionally a hydrocarbyl linking group;

or with formula (c) or (d):-



wherein: R_1 and R_2 are hydrogen,
 R_3 and R_4 are, independently, hydrogen, halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aminoalkyl, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfinyl, substituted or unsubstituted alkylsulfonyl, substituted or unsubstituted carbocyclic aryl, substituted or unsubstituted aralkyl, or substituted or unsubstituted heteroaromatic or heteroalicyclic, and
 R_5 , R_6 and X are as defined above.

AMENDED SHEET





Empfangszeit 19. Juni 22:08

2. A compound as claimed in claim 1 having formula (a) or (b).
3. A compound as claimed in claim 1 or claim 2 having higher activity than cyclopent-2-en-1-one in respect of one or more of the following:-
- activating HSF
 - inhibiting NF- κ B
 - inhibiting the replication of HSV-1
 - inhibiting the replication of Sendai virus.
4. A compound for use in medicine according to any preceding claim, wherein X is an Si-containing group.
5. A compound for use in medicine according to any preceding claim, wherein R_7 , R_8 and R_9 are substituted alkyl, aryl or substituted aryl.
6. A compound for use in medicine according to any preceding claim, wherein X comprises at least 4 carbon atoms.
7. A compound for use in medicine according to claim 1 or any of claims 3-6, said compound having formula (c) or (d), wherein R_3 and/or R_4 comprises no more than 7 carbon atoms.
8. A compound for use in medicine according to claim 1 or any of claims 3-6, said compound having formula (c) or (d), wherein a hydrocarbyl side chain is not present at positions R_3 and/or R_4 .
9. A compound for use in medicine according to claim 8, wherein R_3 and/or R_4 is hydrogen.
10. R-(+)-4-tert-butyltrimethylsilyloxy-cyclopent-2-en-1-one.
11. S-(-)-4-tert-butyltrimethylsilyloxy-cyclopent-2-en-1-one.

43

12. A compound for use in medicine according to any of claims 1 - 9 which is an S-enantiomer.

13. A compound for use in medicine with formula (i), (ii), (iii) or (iv):-



wherein Z is hydrogen or a halogen, R is an optionally substituted hydrocarbyl group including up to 8 carbon atoms, or a moiety incorporating at least one heteroatom and up to 50 carbon atoms, at least one of R¹ and R² in formula (iii) incorporates one or more heteroatoms and up to 30 or 50 carbon atoms, at least one of R¹ and R² in formula (iv) is an optionally substituted hydrocarbyl group, and X and Y are absent or are linking groups.

14. The use of a compound in the preparation of a medicament for treating a viral-mediated disorder, wherein the compound is as described in any of claims 1 to 13.

15. The use of a compound in the preparation of a medicament for treating a bacterial-mediated disorder, wherein the compound is as described in any of claims 1 to 13.

19-06-2001

GB 000001086

44

16. The use of a compound in the preparation of a medicament for treating a disorder mediated by radiation, wherein the compound is as described in any of claims 1 to 13.
17. The use of a compound in the preparation of a medicament for treating an inflammatory disorder, wherein the compound is as described in any of claims 1 to 13.
18. The use of a compound in the preparation of a medicament for treating a disorder of the immune system, wherein the compound is as described in any of claims 1 to 13.
19. The use of a compound in the preparation of a medicament for treating ischemia, wherein the compound is as described in any of claims 1 to 13.
20. The use of a compound in the preparation of a medicament for treating arteriosclerosis, wherein the compound is as described in any of claims 1 to 13.
21. The use of a compound in the preparation of a medicament for treating a disorder involving cell proliferation, wherein the compound is as described in any of claims 1 to 13.
22. The use according to claim 21, wherein the disorder is a cancer
23. The use of a compound in the preparation of a medicament for treating a disorder involving damage to cells or killing of cells, wherein the compound is as described in any of claims 1 to 13.
24. The use of a compound in the preparation of a medicament for treating diabetes, wherein the compound is as described in any of claims 1 to 13.

45

25. The use of a compound in the preparation of a medicament for treating a disorder involving calcium loss or deficiency, wherein the compound is as described in any of claims 1 to 13.
26. The use of a compound in the preparation of a medicament for treating a disorder affecting aquatic organisms, wherein the compound is as described in any of claims 1 to 13.
27. The use according to claim 26 wherein the disorder is a viral disorder.
28. The use of a compound in treating a plant disorder, wherein the compound is a compound as described in any of claims 1 to 13.
29. The use according to claim 28, wherein the plant disorder is a viral disorder.
30. The use of a compound as a research tool for the analysis of one or more of the following: HSF, NF- κ B, the heat shock response, viral replication, viral-mediated disorders, bacterial-mediated disorders, disorders mediated by radiation (e.g. by UV-radiation), inflammatory disorders, disorders of the immune system, ischemia, arteriosclerosis, disorders involving cell proliferation, disorders involving damage to, or killing of cells, or diabetes; disorders involving calcium loss or deficiency, disorders affecting aquatic organisms or plant disorders, wherein the compound is as described in any of claims 1 to 13.
31. A novel compound having a formula as described in claim 13, wherein the compound is not a compound as shown in Figure 2.
32. A pharmaceutical composition comprising a compound as described in any preceding claim and optionally including a pharmaceutically acceptable carrier
33. Food for an aquatic organism comprising a compound as described in any of claims 1 to 13.

34. Food according to claim 33, wherein the food is fish food or crustacean food.
35. An aquaculture system comprising a compound as described in any of claims 1 to 13.
36. The invention as substantially hereinbefore described.
- 